Brazil has only one publicly listed company devoted entirely to biotechnology — and it just turned its first operating profit in years, on the back of an insulin factory it spent a decade building in the hills of Minas Gerais. Full nameBiomm S.A. Ticker / exchangeBIOM3 — B3 (São Paulo) HeadquartersNova Lima, Minas Gerais, Brazil SectorHealthcare / Biotechnology EmployeesNot disclosed in available sources Market value (market cap)R$848.5m (~US$164m) Yearly sales — FY2025 (revenue)R$269.3m (~US$52.1m) Net profit — FY2025–R$6.7m (–~US$1.3m) Net margin (TTM)4.6% — thin, but positive for the first time …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Latest coverage
AgroGalaxy, Fertilizantes Heringer, and Biomm Post Losses in Q1 2024
Brazil’s Biomm Pharma signs agreement with Chinese CanSino to import Covid-19 vaccine
Brazil’s health regulator authorizes Biomm to conduct phase 3 trials of anti-Covid drug
Biomm closes deal to supply Covid-19 drug ‘Leronlimab’ to Brazil
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →